Full title: Study of INBRX-109 in Conventional Chondrosarcoma (ChonDRAgon)
Age: 18-85
Phase: 2
Locations:
London:
- University College London Hospital (UCL)
- Royal Marsden NHS Foundation Trust
Manchester:
- The Christie NHS Foundation Trust
Oxford:
- Churchill Hospital
Brief summary:
This is a trial of INBRX-109 for patients with conventional chondrosarcoma which is metastatic or cannot be removed by surgery. Patients will be randomly allocated to receive INBRX-109 treatment or a placebo. INBRX-109 is an antibody drug targeting a specific receptor (DR5). Patients won’t know whether they receive the INBRX-109 treatment or a placebo during the study.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.
